Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SDHA | P31040 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030086 | 0.79 | MAOB (0.61) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5219360 | 0.71 | MAOA (0.38) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL8010961 | 0.70 | MAOA (0.52) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL8010967 | 0.70 | MAOA (0.52) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7985431 | 0.68 | MAOA (0.40) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7020234 | 0.67 | MAOB (0.61) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7805454 | 0.67 | MAOA (0.47) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL8359085 | 0.67 | MAOA (0.42) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL8359082 | 0.67 | MAOA (0.42) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7815497 | 0.66 | MAOA (0.50) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | MAOB 2698/4885MAOA 2791/4885PTGS1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.